What's in Vical's DNA?

With proprietary platform technology, multiple validating partnerships, advanced clinical programs, a pool of well-qualified, proven talent, and a history of development success, Vical is driving toward the commercialization of innovative infectious disease vaccines and cancer immunotherapies.

PLATFORM TECHNOLOGY

Broad applicability, convenience, safety, repeat administration, ease of manufacturing, cost-effectiveness. Read more

COMMERCIAL OPPORTUNITY

Vical’s Allovectin-7 ^® immunotherapy is nearing completion of a pivotal Phase 3 trial in patients with metastatic melanoma, with an initial market potential of up to $500 million. Read more

HISTORY OF SUCCESS

With more than a dozen programs at various stages of development from research through commercialization, many funded by partners, Vical’s steady progress supports growing acceptance of its platform. Read more

EXTRAORDINARILY TALENTED TEAM

Vical is a purpose-driven team of 115 extraordinarily skilled individuals from some 20 different countries, led by a hand-picked management team. Read more

CONNECT WITH US

P. 858 646 1100 10390 Pacific Center Court, San Diego, California 92121

This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.